Arbutus Biopharma Corp

A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).

ABUS | US

Overview

Corporate Details

ISIN(s):: CA03879J1003 (+2 more)
LEI:
Country:: United States of America
Address:: 701 VETERANS CIRCLE, 18974 WARMINSTER
Website:: https://www.arbutusbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on virology, with a primary mission to develop a functional cure for chronic hepatitis B virus (HBV) infection. The company's strategy centers on developing combination drug regimens that attack the virus through multiple, complementary mechanisms. This multi-pronged approach aims to suppress viral DNA replication, reduce viral antigens (specifically HBsAg), and boost the host's immune response. Its innovative virology portfolio is led by imdusiran, an RNAi therapeutic being investigated as a cornerstone therapy in its HBV clinical studies. Arbutus leverages a team with deep scientific and commercial expertise to advance its pipeline for conditions with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Arbutus Biopharma Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Arbutus Biopharma Corp

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Arbutus Biopharma Corp via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Lineage Cell Therapeutics Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	Israel	LCTX
Lineage Cell Therapeutics, Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	United States of America	LCTX
Lipigon Pharmaceuticals AB Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.	Sweden	LPGO
Lipocine Inc. Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.	United States of America	LPCN
Lipum AB Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.	Sweden	LIPUM
Liquidia Corp Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.	United States of America	LQDA
LISATA THERAPEUTICS, INC. Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.	United States of America	LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.	United States of America	LIXT
Longeveron Inc. Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.	United States of America	LGVN
Lonza Group AG A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.	Switzerland	LONN